Differences in healthcare expenditure estimates according to statistical approach: A nationwide claims database study on patients with hepatocellular carcinoma.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 04 10 2019
accepted: 25 07 2020
entrez: 14 8 2020
pubmed: 14 8 2020
medline: 8 10 2020
Statut: epublish

Résumé

Disease-associated healthcare expenditures are generally calculated using matched comparisons or regression-based analyses, but little is known about their differences in estimates. This aim of this study was to compare the differences between disease-associated healthcare expenditures estimated using these 2 methods. In this retrospective cohort study, a matched comparison was first conducted by matching cases with controls using sex, age, and comorbidities to estimate disease-associated expenditures. The cases were then used in a fixed-effects analysis that compared expenditures before and after disease occurrence. The subjects were adults (≥20 years) with primary hepatocellular carcinoma (HCC) who underwent treatment (including surgical resection, locoregional therapy, transcatheter arterial chemoembolization, and transarterial embolization) at a Japanese hospital between April 2010 and March 2018. We calculated the total healthcare expenditures per patient per month according to treatment and disease phase (initial, continuing, and terminal). There were 14,923 cases in the initial/continuing phases and 15,968 cases in the terminal phase. In the initial/continuing phases, 3,552 patients underwent surgical resection only, with HCC-associated expenditures of $5,555 according to the matched comparison and $5,889 according to the fixed-effects analysis (proportional difference: 94.3%). The initial phase expenditures were approximately 9% higher in the fixed-effects analysis, whereas the continuing phase expenditures were approximately 7% higher in the matched comparison. The expenditures in the terminal phase were 93.1% higher in the fixed-effects analysis. The 2 methods produced similar estimates of HCC-associated healthcare expenditures in the initial/continuing phases. However, terminal phase expenditures were substantially different between the methods.

Identifiants

pubmed: 32790706
doi: 10.1371/journal.pone.0237316
pii: PONE-D-19-27783
pmc: PMC7425973
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0237316

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Hepatology. 2016 Feb;63(2):428-36
pubmed: 26524695
Aliment Pharmacol Ther. 2015 Mar;41(6):544-63
pubmed: 25619871
Am J Med Sci. 2017 Oct;354(4):362-369
pubmed: 29078840
J Manag Care Pharm. 2011 Sep;17(7):531-46
pubmed: 21870894
Am J Med. 1996 Oct;101(4):422-34
pubmed: 8873514
BMJ. 2018 Jul 18;362:k2817
pubmed: 30021785
JAMA Intern Med. 2016 Jan;176(1):65-73
pubmed: 26595724
Ann Intern Med. 2015 Mar 17;162(6):397-406
pubmed: 25775312
Hepatology. 2016 Apr;63(4):1135-44
pubmed: 26707033
N Engl J Med. 2011 Sep 22;365(12):1118-27
pubmed: 21992124
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
BMC Health Serv Res. 2012 Dec 15;12:459
pubmed: 23241078
Aliment Pharmacol Ther. 2004 Jun 1;19(11):1159-72
pubmed: 15153169
Curr Oncol. 2016 Jun;23(3):e196-220
pubmed: 27330357
Clin Gastroenterol Hepatol. 2012 May;10(5):547-54
pubmed: 22210536
J Hepatol. 2009 Jan;50(1):89-99
pubmed: 18977551
Clin Gastroenterol Hepatol. 2005 Jan;3(1):75-84
pubmed: 15645408
BMC Res Notes. 2016 Feb 03;9:62
pubmed: 26843372
J Natl Cancer Inst. 2008 May 7;100(9):630-41
pubmed: 18445825
Appl Health Econ Health Policy. 2008;6(1):55-65
pubmed: 18774870
Clin Gastroenterol Hepatol. 2017 May;15(5):759-766.e5
pubmed: 27464590
Hepatol Res. 2012 Apr;42(4):376-84
pubmed: 22221694
Clin Gastroenterol Hepatol. 2018 Jan;16(1):106-114.e5
pubmed: 28756056
Ann Intern Med. 2015 Mar 17;162(6):407-19
pubmed: 25775313
Am J Gastroenterol. 2003 Mar;98(3):679-90
pubmed: 12650806
Hepatology. 2017 Apr;65(4):1237-1248
pubmed: 28176349
Hepatology. 2011 Mar;53(3):1020-2
pubmed: 21374666
Ann Hepatol. 2017 Aug 1;16(4):555-564
pubmed: 28611258
Hepatology. 2013 Oct;58(4):1375-84
pubmed: 23300063

Auteurs

Haruhisa Fukuda (H)

Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.

Daisuke Sato (D)

Center for Next Generation of Community Health, Chiba University Hospital, Chiba, Japan.

Kensuke Moriwaki (K)

Comprehensive Unit for Health Economic Evidence Review and Decision Support, Ritsumeikan University, Kyoto, Japan.

Haku Ishida (H)

Department of Medical Informatics & Decision Sciences, Yamaguchi University, Yamaguchi, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH